Balancing the curative intent in treating high-risk Hodgkin’s lymphoma with the long-term risks of the treatment is a major challenge. The exact treatment for adult patients with advanced-stage Hodgkin’s lymphoma can differ significantly from that of pediatric patients. A recent study demonstrated the efficacy of Brentuximab vedotin, an antibody-drug conjugate against the CD30 antibody, when used with multiple chemotherapy agents in adult patients with high-risk Hodgkin’s lymphoma. 1 Here’s Journal Watch on the study entitled, “ Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma ” published in the New England Journal of Medicine , 2022 .
What was the need for the study? Previous studies have demonstrated the efficacy of brentuximab vedotin in adult Hodgkin’s lymphoma patients and its associated adverse events. Its safety and efficacy in a pediatric…
